- Home
- DRMA vs CWD Comparison
DRMA vs CWD Comparison
Compare DRMA & CWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRMA
- CWD
- Stock Information
- Founded
- DRMA 2014
- CWD 2009
- Country
- DRMA United States
- CWD United States
- Employees
- DRMA N/A
- CWD N/A
- Industry
- DRMA Biotechnology: Pharmaceutical Preparations
- CWD Real Estate
- Sector
- DRMA Health Care
- CWD Finance
- Exchange
- DRMA Nasdaq
- CWD Nasdaq
- Market Cap
- DRMA 4.5M
- CWD 4.7M
- IPO Year
- DRMA 2021
- CWD 2023
- Fundamental
- Price
- DRMA $0.60
- CWD $3.54
- Analyst Decision
- DRMA Strong Buy
- CWD
- Analyst Count
- DRMA 1
- CWD 0
- Target Price
- DRMA $3.00
- CWD N/A
- AVG Volume (30 Days)
- DRMA 94.5K
- CWD 18.6K
- Earning Date
- DRMA 08-06-2025
- CWD 08-11-2025
- Dividend Yield
- DRMA N/A
- CWD N/A
- EPS Growth
- DRMA N/A
- CWD N/A
- EPS
- DRMA N/A
- CWD N/A
- Revenue
- DRMA N/A
- CWD $35,429,000.00
- Revenue This Year
- DRMA N/A
- CWD N/A
- Revenue Next Year
- DRMA N/A
- CWD $31.12
- P/E Ratio
- DRMA N/A
- CWD N/A
- Revenue Growth
- DRMA N/A
- CWD N/A
- 52 Week Low
- DRMA $0.57
- CWD $3.00
- 52 Week High
- DRMA $5.00
- CWD $18.40
- Technical
- Relative Strength Index (RSI)
- DRMA 29.24
- CWD 44.15
- Support Level
- DRMA $0.57
- CWD $3.18
- Resistance Level
- DRMA $0.63
- CWD $3.90
- Average True Range (ATR)
- DRMA 0.04
- CWD 0.39
- MACD
- DRMA -0.01
- CWD 0.07
- Stochastic Oscillator
- DRMA 11.55
- CWD 30.77
About DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.
About CWD CaliberCos Inc.
CaliberCos Inc is an asset management firm whose primary goal is to enhance the wealth of investors seeking to make investments in middle-market assets. The company's funds include investment vehicles focused on real estate, private equity, and debt facilities. The company earns asset management fees calculated as a percentage of managed capital in funds and offerings. The company markets services through direct sales to private investors, wholesaling to investment advisers, direct sales to family offices and institutions and through in-house client services. The company operates into three reportable segments: Fund Management, Development, and Brokerage. The majority of revenue is derived from the fund management fees segment.